Clinical Trials Logo

Septic Shock Hyperdynamic clinical trials

View clinical trials related to Septic Shock Hyperdynamic.

Filter by:
  • None
  • Page 1

NCT ID: NCT04507672 Not yet recruiting - Clinical trials for Septic Shock Hyperdynamic

Acetated Ringer's Solution Versus Saline in Patients With Septic Shock

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

The primary aim of this trial is to compare the effect of acetated ringer's solution with that of saline for therapy on the incidence and development of major adverse renal events among septic shock patients. The investigators hypothesize that use of acetated ringer's solution for resuscitation among septic shock patients will reduce the incidence of major adverse kidney events.

NCT ID: NCT03788837 Completed - Clinical trials for Septic Shock Hyperdynamic

Ilomedin in Septic Shock With Persistent Microperfusion Defects (I-MICRO)

I-MICRO
Start date: July 3, 2019
Phase: Phase 3
Study type: Interventional

Septic shock remains a major cause of death in critically ill patients. Alterations in microcirculation have long been proposed as a key pathophysiological factor of organ dysfunction and death in septic shock patients. Persistence of mottling, prolonged skin recoloration time and cyanosis of the extremities are the easily and frequently observed manifestations of these microcirculatory disorders. Ilomedin is a prostaglandin analog with a potent vasodilatory effect together with anti-thrombotic properties (inhibition of platelet aggregation) preferentially at the microcirculatory level. An increase in cardiac output with increased arterial oxygen delivery has been observed in clinical and preclinical studies with no episodes of hypotension. Improvement in mesenteric perfusion has moreover been observed in experimental sepsis using Ilomedin. Our group has furthermore reported that administration of Ilomedin in patients with refractory septic shock (peripheral hypoperfusion) resulted in a rapid and sustained improvement in peripheral perfusion. Altogether, Ilomedin may prevent or improve recovery of organ dysfunction in septic shock patients through recruitment of the microcirculation and, thereby, ultimately improve outcome.